Trial Roundup

ASH Clinical News’ Associate Editors select clinical trials to keep an eye on.

  • December 2016: Evaluating Acalabrutinib for Hematologic Malignancies, Minimizing Menorrhagia in Women With Type 1 Von Willebrand Disease, and more Tuesday, November 22nd, 2016 | December 2016, Volume 2, Issue 12

    LEUKEMIA David Steensma, MD Dana-Farber Cancer Institute Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia (NCT02841540) Study Design: Non-randomized, parallel-assignment, open-label safety/efficacy study Study Start Date: August 2016 Estimated Study Completion Date: March 2019 Study Status: Currently […]

  • November 2016: Introducing the Beat AML Master Trial, and more Thursday, October 27th, 2016 | November 2016, Volume 2, Issue 11

    The Beat AML Master Trial Study Design: Observational, prospective cohort study Study Start Date: November 2016 Estimated Study Completion Date: November 2023 Study Status: Currently recruiting participants Estimated Enrollment: 500 Sponsor: The Leukemia & Lymphoma Society The American Society of Hematology and The Leukemia & Lymphoma Society (LLS) have teamed up to raise awareness and […]

  • September 2016: Biomarker-Directed Trial for AML or MDS, Safety and Efficacy of BMN 270 for Hemophilia, and more Thursday, September 1st, 2016 | September 2016, Volume 2, Issue 9

    LEUKEMIA David Steensma, MD Dana-Farber Cancer Institute Controlled Study of Rigosertib Versus Physician’s Choice of Treatment in MDS Patients After Failure of an HMA (INSPIRE) (NCT02562443) Study Design: Randomized, parallel-assignment, open-label safety/efficacy study Study Start Date: October 2015 Estimated Study Completion Date: September 2018 Study Status: Currently recruiting participants Estimated Enrollment: 225 Sponsor: Onconova Therapeutics, […]

  • June 2016: T Cell Therapy for Previously Treated Multiple Myeloma, Emicizumab in Hemophilia A Patients With Inhibitors, and more Monday, May 23rd, 2016 | June 2016, Volume 2, Issue 6

    LEUKEMIA David Steensma, MD Dana-Farber Cancer Institute A Two-Arm Phase II Clinical Study of the Clinical Efficacy and Safety of Tosedostat in Patients With Myelodysplastic Syndromes (MDS) After Failure of Hypomethylating Agent-Based Therapy (NCT02452346) study design: Non-randomized, open-label, single-group assignment safety/efficacy study study start date: February 2015 estimated study completion date: September 2018 study status: […]

  • April 2016: Lenalidomide Plus R-CHOP in DLBCL, New Gene Therapies for Hemophilia B , and more Tuesday, March 29th, 2016 | April 2016, Volume 2, Issue 4

    LEUKEMIA David Steensma, MD Dana-Farber Cancer Institute A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations (NCT02283177) Study Design: Non-randomized, open-label, parallel-assignment, safety study Study Start Date: January 2015 Estimated Study Completion Date: July 2017 Study Status: Currently recruiting participants Estimated Enrollment: 48 […]

1 of 3
back to top